Cumulus Neuroscience validates NeuLogiq platform for home-based cognitive assessment in ALS and FTD patients
Executive summary: Cumulus Neuroscience announced the publication of a study in Scientific Reports showing that its NeuLogiq® platform is suitable for home use by patients with ALS and FTD. It enables remote cognitive assessment, reducing the burden of clinic visits and opening opportunities for broader use in clinical trials and routine neurology practice.
Who is involved: Cumulus Neuroscience, ALS and FTD patients, the Scientific Reports journal, and the researchers behind the CNS-102 study.
Likely next: The company may pursue regulatory clearance for home use, seek partnerships with pharmaceutical firms for trial deployment, and explore reimbursement pathways with payers.
The company announced that final results of the CNS-102 study, published in Scientific Reports, demonstrate that the NeuLogiq® system can be used effectively by patients with significant motor and cognitive impairments in a home setting. This validation addresses a key barrier in neurodegenerative disease research and care, where frequent clinic visits are burdensome. The findings position NeuLogiq as a candidate tool for remote monitoring in clinical trials and routine care, potentially expanding its market reach.
Timeline
- — Cumulus Neuroscience gibt die Veröffentlichung eines Artikels in der Fachzeitschrift „Scientific Reports“ bekannt, der belegt, dass die NeuLogiq®-Plattform für die multimodale kognitive Beurteilung von Menschen mit ALS und FTD zu Hause geeignet und einsetzbar ist (PR Newswire)
Analysis — what this means
Sectors affected
- Digital neurohealth
- Remote patient monitoring
Key entities
Sources
Open the full interactive case file on Beyond →